Antiplatelet Effects of Flavonoids Mediated by Inhibition of Arachidonic Acid Based Pathway

Abstract

Flavonoids, important components of human diet, have been claimed to possess a significant antiplatelet potential, in particular due to their effects on the arachidonic acid cascade. Due to variable and incomplete results, this study was aimed at delivering a detailed analysis of the effects of 29 structurally relevant, mainly natural flavonoids on three consecutive steps of the arachidonic acid cascade.

Only the isoflavonoids genistein and daidzein were shown to possess a marked cyclooxygenase-1 inhibitory activity, which was higher than that of acetylsalicylic acid using the isolated ovine enzyme, and physiologically relevant, although lower than acetylsalicylic acid in human platelets. None of the tested flavonoids possesses an effect on thromboxane synthase in a clinically achievable concentration. Contrarily, many flavonoids, particularly those possessing an isolated 7-hydroxyl group and/or a 4′-hydroxyl group, acted as antagonists on thromboxane receptors. Interestingly, the substitution of the free 7-hydroxyl group by glucose might not abolish the activity.

In conclusion, the consumption of few flavonoids in a diet, particularly of the isoflavonoids genistein and daidzein, may positively influence platelet aggregation.

Key words

aggregation - arachidonic acid - cyclooxygenase - flavonoid - platelet - thromboxane

• References

• 1 Michelson AD. Platelets. 2nd. edition. Amsterdam: Academic Press (Elsevier); 2007
• 2 Hsiao G, Ko FN, Jong TT, Teng CM. Antiplatelet action of 3′,4′-diisovalerylkhellactone diester purified from Peucedanum japonicum Thunb. Biol Pharm Bull 1998; 21: 688-692
• 3 Mower RL, Landolfi R, Steiner M. Inhibition in vitro of platelet aggregation and arachidonic acid metabolism by flavone. Biochem Pharmacol 1984; 33: 357-363
• 4 Pilgrim T, Windecker S. Antiplatelet therapy for secondary prevention of coronary artery disease. Heart 2014; 100: 1750-1756
• 5 Kontogiorgis C, Hadjipavlou-Litina D. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis. Curr Med Chem 2010; 17: 3162-3214
• 6 Kim JM, Yun-Choi HS. Anti-platelet effects of flavonoids and flavonoid-glycosides from Sophora japonica . Arch Pharm Res 2008; 31: 886-890
• 7 Bojic M, Debeljak Z, Tomicic M, Medic-Saric M, Tomic S. Evaluation of antiaggregatory activity of flavonoid aglycone series. Nutrition journal 2011; 10: 73
• 8 Tzeng SH, Ko WC, Ko FN, Teng CM. Inhibition of platelet aggregation by some flavonoids. Thromb Res 1991; 64: 91-100
• 9 Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 2005; 3: 369-376
• 10 Mladenka P, Zatloukalova L, Filipsky T, Hrdina R. Cardiovascular effects of flavonoids are not caused only by direct antioxidant activity. Free Radic Biol Med 2010; 49: 963-975
• 11 Kelly C, Hunter K, Crosbie L, Gordon MJ, Dutta-Roy AK. Modulation of human platelet function by food flavonoids. Biochem Soc Trans 1996; 24: 197S
• 12 Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003; 1: 1079-1088
• 13 Fuentes E, Palomo M. Antiplatelet effects of natural bioactive compounds by multiple targets: Food and drug interactions. J Funct Foods 2014; 6: 73-81
• 14 Navarro-Nunez L, Castillo J, Lozano ML, Martinez C, Benavente-Garcia O, Vicente V, Rivera J. Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem 2009; 57: 1589-1594
• 15 Navarro-Nunez L, Lozano ML, Palomo M, Martinez C, Vicente V, Castillo J, Benavente-Garcia O, Diaz-Ricart M, Escolar G, Rivera J. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J Agric Food Chem 2008; 56: 2970-2976
• 16 Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342: 1007-1011
• 17 Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 1996; 156: 637-642
• 18 Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002; 76: 560-568
• 19 Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr 2002; 75: 880-886
• 20 McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012; 95: 454-464
• 21 Mursu J, Voutilainen S, Nurmi T, Tuomainen TP, Kurl S, Salonen JT. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: the Kuopio ischaemic heart disease risk factor study. Br J Nutr 2008; 100: 890-895
• 22 Mosawy S, Jackson DE, Woodman OL, Linden MD. Treatment with quercetin and 3′,4′-dihydroxyflavonol inhibits platelet function and reduces thrombus formation in vivo . J Thromb Thrombolysis 2013; 36: 50-57
• 23 Gryglewski RJ, Korbut R, Robak J, Swies J. On the mechanism of antithrombotic action of flavonoids. Biochem Pharmacol 1987; 36: 317-322
• 24 Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 1998; 128: 593-597
• 25 Janssen K, Mensink RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC, Katan MB. Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr 1998; 67: 255-262
• 26 Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA, Gibbins JM. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharmacol 2010; 159: 1312-1325
• 27 Guerrero JA, Navarro-Nunez L, Lozano ML, Martinez C, Vicente V, Gibbins JM, Rivera J. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol 2007; 64: 133-144
• 28 Lindahl M, Tagesson C. Flavonoids as phospholipase A2 inhibitors: importance of their structure for selective inhibition of group II phospholipase A2. Inflammation 1997; 21: 347-356
• 29 Beretz A, Stierle A, Anton R, Cazenave JP. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin. Biochem Pharmacol 1981; 31: 3597-3600
• 30 Jackson SP. The growing complexity of platelet aggregation. Blood 2007; 109: 5087-5095
• 31 Macakova K, Rehakova Z, Mladenka P, Karlickova J, Filipsky T, Riha M, Prasad AK, Parmar VS, Jahodar L, Pavek P, Hrdina R, Saso L. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 2012; 94: 2681-2686
• 32 Corvazier E, Maclouf J. Interference of some flavonoids and non-steroidal anti-inflammatory drugs with oxidative metabolism of arachidonic acid by human platelets and neutrophils. Biochim Biophys Acta 1985; 835: 315-321
• 33 Chi YS, Jong HG, Son KH, Chang HW, Kang SS, Kim HP. Effects of naturally occurring prenylated flavonoids on enzymes metabolizing arachidonic acid: cyclooxygenases and lipoxygenases. Biochem Pharmacol 2001; 62: 1185-1191
• 34 Laughton MJ, Evans PJ, Moroney MA, Hoult JR, Halliwell B. Inhibition of mammalian 5-lipoxygenase and cyclo-oxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability. Biochem Pharmacol 1991; 42: 1673-1681
• 35 Moroney MA, Alcaraz MJ, Forder RA, Carey F, Hoult JR. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids. J Pharm Pharmacol 1988; 40: 787-792
• 36 Wang H, Nair MG, Strasburg GM, Booren AM, Gray I, Dewitt DL. Cyclooxygenase active bioflavonoids from Balaton tart cherry and their structure activity relationships. Phytomedicine 2000; 7: 15-19
• 37 Kim DH, Jung EA, Sohng IS, Han JA, Kim TH, Han MJ. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch Pharm Res 1998; 21: 17-23
• 38 Williamson G. The use of flavonoid aglycones in in vitro systems to test biological activities: based on bioavailability data, is this a valid approach?. Phytochem Rev 2002; 1: 215-222
• 39 Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, Kamphues J, Wolffram S. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 2008; 138: 1417-1420
• 40 Righi G, Antonioletti R, Proietti Silvestri I, DʼAntona N, Lambusta D, Bovicelli P. Convergent synthesis of mosloflavone, negletein and baicalein from crysin. Tetrahedron Lett 2010; 66: 1294-1298
• 41 Cayman Chemical Company. COX Inhibitor Screening Assay Kit. Available at. http://www.caymanchem.com/app/template/Product.vm/catalog/560131 Accessed January 6, 2012.
• 42 Chang TS, Kim HM, Lee KS, Khil LY, Mar WC, Ryu CK, Moon CK. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets. Biochem Pharmacol 1997; 54: 259-268